| 13.88 -0.77 (-5.26%) | 08-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.14 | 1-year : | 20.02 |
| Resists | First : | 14.68 | Second : | 17.14 |
| Pivot price | 13.26  |
|||
| Supports | First : | 12.01 | Second : | 10.36 |
| MAs | MA(5) : | 13.93 |
MA(20) : | 12.89 |
| MA(100) : | 10.18 |
MA(250) : | 10.83 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 91.6 |
D(3) : | 90.7 |
| RSI | RSI(14): 61.2 |
|||
| 52-week | High : | 14.93 | Low : | 7.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ORIC ] has closed below upper band by 35.2%. Bollinger Bands are 40.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.51 - 14.59 | 14.59 - 14.65 |
| Low: | 13.6 - 13.68 | 13.68 - 13.75 |
| Close: | 13.74 - 13.88 | 13.88 - 14.01 |
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Fri, 21 Aug 2026
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Thu, 20 Aug 2026
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month High - Here's Why - MarketBeat
Fri, 07 Aug 2026
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 60% Upside Potential - DirectorsTalk Interviews
Fri, 07 Aug 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mon, 03 Aug 2026
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary - TradingView
Mon, 03 Aug 2026
ORIC Starts Global Prostate Cancer Trial Expected to Enroll About 600 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 116.4 (%) |
| Shares Short | 22,050 (K) |
| Shares Short P.Month | 21,060 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -112 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -10.68 |
| PEG Ratio | 0 |
| Price to Book value | 3.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|